$SLS News

SELLAS Says Arbitrator Dismisses Its Claims Against 3D Medicines, Orders SELLAS To Pay Approximately $1M In Legal Fees

SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up

Sellas Life Sciences: REGAL Trial's Delayed Events Signal Selection Bias

SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall

Why Sellas Remains A Strong Sell After Doubling In Price

SELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?

Sellas Life Sciences Shares Break Out To New 52-Week High: What's Driving The Momentum?

Sellas Life Sciences: The AML Platform Is More Interesting Than The Binary Event

SELLAS Stock Hits New Highs: What's Happening Today?

Why SELLAS Life Sciences Stock Is Surging Thursday

SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute

SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities – A Look At The Important Numbers

Jim Cramer on SELLAS: “It’s a Great Spec”

SELLAS Life Sciences Group (SLS) Is Up 21.4% After REGAL Nears Topline Readout And Cramer Endorsement

SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout

Sellas Life Sciences: The Internal Inconsistency Of An Assumed Positive REGAL Readout

SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS

SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms

SLS Stock Heads For Its Best Month This Year Ahead Of Key AML Trial Readout

Sellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish Signal